Tadalafil SZ


Tadalafil SZ is a medication used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. Tadalafil is a PDE5 inhibitor which increases blood flow to the penis with sexual arousal. It also dilates blood vessels in the lungs, which lowers the pulmonary artery pressure.

A meta‐analysis found that tadalafil 5 mg once a day is an effective treatment for lower urinary tract symptoms caused by prostatic hyperplasia. Such treatment had a low rate of side effects. 


Indications for use

  • Erectile dysfunction 
  • Benign prostatic hypertrophy
  • Pulmonary arterial hypertension

    Tadalafil SZ is a high quality product manufactered in Russia at a reasonable price, in contradistinction to the most popular Tadafil's brand name Cialis.

    1 film-coated tablet contains the active ingridient: tadalafil - 5 mg

    The average half-life of tadalafil is 17.5 hours.

    Dosage and administration

    The recommended dosage of Tadalafil-SZ is 5 mg; the drug should be taken at about the same time of the day, regardless of the time of sexual activity.

    The daily dose may be reduced to 2.5 mg (1/2 tablet of 5 mg), depending on individual sensitivity. The maximum daily dose of Tadalafil-SZ is 20 mg.

    The duration of treatment is set by the doctor individually.


    Side effects

    The most common side effects in patients with erectile dysfunction and BPH are headache and dyspepsia, as well as back pain, myalgia.



    • Hypersensitivity to the components of the drug;
    • Usage of drugs containing any organic nitrates;
    • Age below 18 years;
    • The presence of contraindications to sexual activity in patients with diseases of the cardiovascular system;
    • Loss of vision due to non-arterial anterior ischemic neuropathy of the optic nerve (regardless of the connection with the intake of PDE-5 inhibitors);
    • Concomitant use with doxazosin, with other PDE-5 inhibitors, with other treatment options for erectile dysfunction, with guanylate cyclase stimulants such as riotsiguat;
    • Use in patients with chronic renal failure;
    • Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.